+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders



Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders



Drug Design, Development and Therapy 11: 305-312



Metoprolol treatment is well established for chronic heart failure (CHF) patients, but the central nervous system side effects are often a potential drawback. To investigate the impact of metoprolol treatment on change in mental status of CHF patients with clinical psychological disorders (such as depression, anxiety, and burnout syndrome). From February 2013 to April 2016, CHF patients with clinical mental disorders received metoprolol (23.75 or 47.5 mg, qd PO, dose escalated with 23.75 mg each time until target heart rate [HR] <70 bpm was achieved) at the Second Affiliated Hospital of Kunming Medical University. Mental status was assessed by means of the Hospital Anxiety and Depression Scale (HADS) and the Copenhagen Burnout Inventory (CBI) scale. The primary outcome assessed was change in mental status of patients post-metoprolol treatment and the association with reduction in HR achieved by metoprolol. A total of 154 patients (median age: 66.39 years; males: n=101) were divided into eight groups on the basis of their mental status. HR decreased significantly from baseline values in all the groups to <70 bpm in the 12th month, P≤0.0001. The HADS depression and CBI scores significantly increased from baseline throughout the study frame (P≤0.0001 for all groups), but a significant decrease in the HADS anxiety score was observed in patients with anxiety (P≤0.0001 for all groups). Regression analysis revealed no significant correlation in any of the groups between the HR reduction and the change in the HADS/CBI scores, except for a change in the CBI scores of CHF patients with depression (P=0.01), which was HR dependent. Metoprolol treatment worsens the depressive and high burnout symptoms, but affords anxiolytic benefits independent of HR reduction in CHF patients with clinical mental disorders. Hence, physicians need to be vigilant while prescribing metoprolol in CHF patients who present with mental disorders.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059837472

Download citation: RISBibTeXText

PMID: 28182127

DOI: 10.2147/DDDT.S124497


Related references

Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders. Current Medical Research and Opinion 34(1): 141-148, 2017

Improvement in quality of life of Chinese chronic heart failure patients with neuropsychiatric complications over 12-months post-treatment with metoprolol. Medicine 98(4): E14252-E14252, 2019

Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). Journal of the American College of Cardiology 40(3): 491-498, 2002

Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). American Journal of Cardiology 92(4): 478-480, 2003

Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study. Circulation. Heart Failure 8(5): 887-896, 2015

The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. Vascular Health and Risk Management 2(2): 139-144, 2007

A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients. International Journal of Cardiology (): -, 2016

Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). American Heart Journal 141(3): 418-421, 2001

Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. Journal Of The American College Of Cardiology. 30(4): 992-996, 1997

Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Congestive Heart Failure 5(4): 184-185, 2002

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169): 2001-2007, 1999

Impact of a metoprolol or carvedilol therapy on the activity of radical scavenger enzymes in the skeletal muscle of patients with chronic heart failure. European Heart Journal 24(Abstract Supplement): 534, August-September, 2003

Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clinical Research in Cardiology 106(9): 711-721, 2017

Combination therapy with metoprolol and felodipine reduce benefit in resting and exercise haemodynamics as compaired with metoprolol alone in patients with severe chronic heart failure. European Heart Journal 20(ABSTR SUPPL ): 497, 1999

Impact of a beta-blocker therapy with metoprolol or carvedilol on the activity of radical scavenger enzymes in the skeletal muscle of patients with chronic heart failure. Circulation 108(17 Supplement): IV-370, October 28, 2003